Robert Jabulowsky has more than 9 years of experience in academic translational cancer research and industrial pharmaceutical development. Dr. Jabulowsky joined BioNTech AG (Mainz, Germany) in 2012. As senior project manager, he is responsible for the management and translation
of innovative therapeutic concepts into clinical testing. Founded in 2008, BioNTech AG is an immunotherapy leader with bench-to-market capabilities, developing truly personalised, well-tolerated and potent treatments
for cancer and other diseases. Established by clinicians and scientists BioNTech is pioneering disruptive technologies ranging from individualised mRNA based medicines through innovative chimeric antigen receptors /T-cell receptor-based products and novel antibody checkpoint immunomodulators.
Robert Jabulowsky holds a diploma in biology and a Ph.D. in
pharmacy from the University of Frankfurt, Germany.